Acorda Therapeutics (NASDAQ: ACOR) was downgraded by Lazard Capital from a “buy” rating to a “neutral” rating in a research note issued on Monday.
Separately, analysts at JPMorgan Chase & Co. (NYSE: JPM) downgraded shares of Acorda Therapeutics from an “overweight” rating to a “neutral” rating in a research note to investors on Monday, January 23rd. They now have a $30.00 price target on the stock. Analysts at MKM Partners upgraded shares of Acorda Therapeutics from a “neutral” rating to a “buy” rating in a research note to investors on Monday, January 9th. They now have a $32.00 price target on the stock, up previously from $26.00. Also, analysts at Rodman & Renshaw reiterated an “underperform” rating on shares of Acorda Therapeutics in a research note to investors on Friday, November 4th. They now have a $18.00 price target on the stock.
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda’s marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.
Acorda Therapeutics opened at 26.29 on Monday. Acorda Therapeutics has a 1-year low of $18.36 and a 1-year high of $33.48. The stock has a 50-day moving average of $24.50 and a 200-day moving average of $24.02. The company has a market cap of $1.043 billion and a price-to-earnings ratio of 48.42.